The SUSTAIN and STEP trial series for semaglutide demonstrated 1015% body weight reduction over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM: The SURMOUNT-1 trial for tirzepatide demonstrated up to 20.9% weight reduction at the highest dose (Jastreboff et al., 2022, NEJM: Retatrutide Phase II data (Jastreboff et al., 2023, NEJM) showed up to 24.2% weight loss, the highest reported for any pharmacological intervention in a randomised trial at the time of publication
GLP-1 and PMOS: The Strongest Case in 2026 GLP-1 receptor agonists including semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda) are the most evidence-supported peptide option for women with PMOS as of 2026
Liquid or pureed diets during flare-ups
Statements Author contributions AW: Visualization, Writing review & editing
What PTs Should Monitor We encourage PTs to track the following during the BPC-157 program: Pain levels (at rest, with motion, and with loading) ROM and mobility progression Tissue tolerance to loading Swelling or inflammation patterns Strength development Neuromuscular control Return-to-function benchmarks Any unusual or unexpected symptoms If something seems off, PTs are encouraged to reach out to Thrive directly.
